Ads
related to: prostate+cancer%2C+cell- nmCRPC Treatment Option
31% Risk of Death Decrease
Visit The Patient Site.
- Dosing & Administration
View Recommended Dosage & Learn
About Drug Interactions Here.
- Clinical Information
Read About A Double-Blind, Placebo-
Controlled, Randomized Study.
- Downloadable Resources
Resources For Physicians & Patients
Available On The Site To Download.
- mHSPC Treatment Option
32% Risk of Death Decrease
Visit The Patient Site.
- Patient Profiles
Explore Patient Profiles To Assess
A Treatment Option.
- nmCRPC Treatment Option
Search results
Alpha Tau Medical Ltd. to Post Q2 2025 Earnings of ($0.13) Per Share, HC Wainwright Forecasts...
ETF DAILY NEWS· 5 days agoAlpha Tau Medical Ltd. (NASDAQ:DRTS – Free Report) – HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Alpha Tau Medical in a research report issued on Wednesday, ...
Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults
WROC Rochester· 2 days agoUSA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years...
Ignoring Colonoscopy Advice; Inflamed Tongue, Then Cancer; Acupuncture for Dry Mouth
MedPage Today· 6 days agoNews, features, and commentary about cancer-related issues
ASCO24: An early look at cancer drug study results
BioPharma Dive via Yahoo Finance· 7 days agoClinical trial abstracts posted Thursday ahead of this year’s ASCO meeting give a peek at anticipated datasets from Immunocore, Merus, J&J and Merck &...
...BioAnalytics and University College London Demonstrates Significant Improvement Over CA125 and...
NBC 10 - FOX 14 Monroe· 7 days agoMercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsy for the early detection of cancer, will present data at the American Society of Clinical Oncology ...
Mercy Bioanalytics Pushing Forward with Plans to Market Ovarian Cancer Blood Test
GenomeWeb News· 2 days agoExtracellular vesicle diagnostics firm Mercy Bioanalytics is making progress in its plans to market and eventually garner US Food and Drug Administration approval for a novel ovarian
Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual...
FOX21 Colorado Springs· 7 days agoEli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio® (abemaciclib; a CDK4/6 inhibitor), Retevmo® (selpercatinib; a rearranged during transfection [RET] inhibitor ...
What Happens to Your Body When You Eat Broccoli Regularly
Eating Well via Yahoo News· 7 days agoRemarkably, this potent substance has been linked to a reduced risk of various cancers, including...
Dog study reveals when's best to spay or neuter for your pet's health
Newsweek· 1 day agoScientists have updated guidelines on when to neuter your dog in light of increasing evidence that...
Candel (CADL) Reports Upbeat Data From Lung Cancer Study
Zacks· 6 days agoCandel's (CADL) CAN-2409 prolongs overall survival in a phase II study for treating patients with advanced non-small cell lung cancer who are non-responsive to immune checkpoint inhibitor therapy.